Hidden genetic causes of congenital heart disease identified

New York, NY [February 20, 2025]—Scientists at the Icahn School of Medicine at Mount Sinai and collaborators have identified novel genetic interactions that may contribute to congenital heart disease (CHD), a common birth defect. Details on their findings were reported in the February 20 online issue of The American Journal of Human Genetics [DOI: 10.1016/j.ajhg.2025.01.024].

“Our research reveals the potential for digenic inheritance—where two genes work together to cause disease—expanding our understanding of the genetic underpinnings of congenital heart disease,” says co-corresponding senior author Yuval Itan, PhD, Associate Professor of Genetics and Genomic Sciences, a core member of The Charles Bronfman Institute for Personalized Medicine, and a member of The Mindich Child Health and Development Institute at the Icahn School of Medicine at Mount Sinai. He co-supervised the study with Bruce Gelb, MD, Gogel Family Professor and Director of The Mindich Institute. “By identifying these gene pairs and their combined effects, we uncover previously hidden genetic risks, which could improve diagnostic precision and open new avenues for personalized treatment strategies.”

Congenital heart disease is the most common congenital anomaly, affecting millions worldwide. Despite decades of research, more than half of CHD cases still lack a molecular diagnosis. By analyzing trio exome sequencing data from affected and unaffected children in the Pediatric Genomic Consortium (PCGC), the team identified 10 novel gene pairs potentially linked to the development of CHD.

“Our work demonstrates that genetic interactions, rather than single-gene causes alone, could play a significant role in congenital heart disease. By developing a method to uncover these interactions, we are broadening the scope of genetic research, which could lead to improved diagnosis, enhanced risk assessment, and more informed genetic counseling,” says first author Meltem Ece Kars, MD, PhD, a postdoctoral fellow in The Bronfman Institute. “As clinical genetic testing advances, integrating digenic models could significantly improve diagnostic yield, offering patients and their families greater clarity about their condition and guiding the development of targeted therapies and interventions.”

The research team used a robust computational method to identify gene pairs that may act together to cause CHD. This innovative approach could transform how genetic studies are conducted for complex diseases, providing deeper insights into the role of genetics in disease development, say the investigators.

The study also paves the way for advancing genetic diagnoses in other complex disorders. “With the tools we’ve developed, our research provides a framework for future studies into genetic interactions that could affect a wide range of human diseases,” says Dr. Itan.

Next, the researchers plan to apply the digenic approach to other disease groups that have traditionally been studied using the monogenic model, potentially explaining some of the missing heritability in these disorders. Ultimately, they aim to extend the digenic approach into a robust polygenic framework capable of identifying multiple disease-causing variants and genes in patients.

“Our findings hold promise for improving genetic diagnoses, offering better risk assessments, and ultimately guiding more personalized treatments for individuals with congenital heart disease,” says Dr. Kars.

The paper is titled “Deciphering the digenic architecture of congenital heart disease using trio exome sequencing data.”

The remaining authors are David Stein (PhD student at the Icahn School of Medicine at Mount Sinai); Peter D. Stenson, (Cardiff University, UK); David N. Cooper, PhD (Cardiff University, UK); Wendy K. Chung, MD, PhD (Boston Children’s Hospital and Harvard Medical School); Peter J. Gruber, MD, PhD (Yale School of Medicine); Christine E. Seidman, MD, (Harvard Medical School, Brigham and Women's Hospital, Howard Hughes Medical Institute); Yufeng Shen, PhD (Columbia University Irving Medical Center); and Martin Tristani-Firouzi, MD (University of Utah School of Medicine).

This research is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health and the U.S. Department of Health and Human Services through grants UM1HL128711, UM1HL098162, UM1HL098147, UM1HL098123, UM1HL128761, and U01HL131003. Additional support was provided by Clinical and Translational Science Awards (CTSA) grant UL1TR004419 from the National Center for Advancing Translational Sciences.

-####-

About the Icahn School of Medicine at Mount Sinai 

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight- member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population.  

The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. Its Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 500 postdoctoral research fellows. 

Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges.  More than 4,500 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.

------------------------------------------------------- 

* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.